U2Bio Co., Ltd. (KOSDAQ:221800)
South Korea
· Delayed Price · Currency is KRW 5,140.00
-350.00 (-6.38%)
At close: Dec 5, 2025
U2Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 |
| Operating Revenue | 25,586 | 25,040 | 30,792 | 69,013 | 11,002 | 9,412 |
| Other Revenue | - | - | - | -0 | - | - |
| Revenue | 25,586 | 25,040 | 30,792 | 69,013 | 11,002 | 9,412 |
| Revenue Growth (YoY) | -2.62% | -18.68% | -55.38% | 527.29% | 16.90% | - |
| Cost of Revenue | 20,385 | 20,001 | 22,573 | 42,374 | 8,135 | 7,208 |
| Gross Profit | 5,201 | 5,039 | 8,219 | 26,639 | 2,867 | 2,204 |
| Selling, General & Admin | 5,199 | 5,644 | 7,432 | 8,351 | 1,921 | 1,412 |
| Research & Development | 2,249 | 2,110 | 1,685 | 2,129 | 157.15 | 285.47 |
| Amortization of Goodwill & Intangibles | - | - | - | - | 5.99 | 11.85 |
| Other Operating Expenses | - | - | - | - | 0.57 | 0.3 |
| Operating Expenses | 7,701 | 7,967 | 9,557 | 10,931 | 2,181 | 1,760 |
| Operating Income | -2,499 | -2,928 | -1,338 | 15,708 | 685.8 | 443.79 |
| Interest Expense | -39.8 | -42.62 | -36.32 | -86.25 | -374.37 | -309.98 |
| Interest & Investment Income | 1,127 | 1,287 | 1,355 | 555.15 | 9.96 | 13.53 |
| Currency Exchange Gain (Loss) | 13.36 | 50.03 | 5.55 | 26.78 | 10.48 | -9.6 |
| Other Non Operating Income (Expenses) | -86.22 | -0.66 | 96.98 | -43.48 | -60.19 | -0.98 |
| EBT Excluding Unusual Items | -1,485 | -1,634 | 83.63 | 16,160 | 271.68 | 136.76 |
| Gain (Loss) on Sale of Assets | - | - | 6.21 | -71.54 | - | - |
| Asset Writedown | 38.18 | 13.64 | -51.69 | -22.7 | - | - |
| Pretax Income | -1,447 | -1,620 | 38.15 | 16,066 | 271.68 | 136.76 |
| Income Tax Expense | 1,539 | 1,220 | -607.74 | 2,906 | - | - |
| Net Income | -2,986 | -2,840 | 645.9 | 13,160 | 271.68 | 136.76 |
| Net Income to Common | -2,986 | -2,840 | 645.9 | 13,160 | 271.68 | 136.76 |
| Net Income Growth | - | - | -95.09% | 4743.99% | 98.66% | - |
| Shares Outstanding (Basic) | 11 | 11 | 10 | 10 | 1 | 1 |
| Shares Outstanding (Diluted) | 11 | 11 | 10 | 10 | 1 | 1 |
| Shares Change (YoY) | 0.84% | 10.09% | 1.51% | 598.90% | 22.57% | - |
| EPS (Basic) | -265.03 | -251.66 | 63.00 | 1303.00 | 188.00 | 116.00 |
| EPS (Diluted) | -265.03 | -251.66 | 63.00 | 1303.00 | 188.00 | 116.00 |
| EPS Growth | - | - | -95.17% | 593.09% | 62.07% | - |
| Free Cash Flow | -647.74 | -1,775 | -2,769 | 23,439 | -1,482 | -335.41 |
| Free Cash Flow Per Share | -57.50 | -157.22 | -270.09 | 2320.73 | -1025.56 | -284.50 |
| Gross Margin | 20.33% | 20.13% | 26.69% | 38.60% | 26.05% | 23.42% |
| Operating Margin | -9.77% | -11.69% | -4.35% | 22.76% | 6.23% | 4.71% |
| Profit Margin | -11.67% | -11.34% | 2.10% | 19.07% | 2.47% | 1.45% |
| Free Cash Flow Margin | -2.53% | -7.09% | -8.99% | 33.96% | -13.47% | -3.56% |
| EBITDA | -1,729 | -2,050 | -419.13 | 16,596 | 917.55 | 641.31 |
| EBITDA Margin | -6.76% | -8.19% | -1.36% | 24.05% | 8.34% | 6.81% |
| D&A For EBITDA | 770.04 | 877.21 | 918.87 | 887.97 | 231.75 | 197.52 |
| EBIT | -2,499 | -2,928 | -1,338 | 15,708 | 685.8 | 443.79 |
| EBIT Margin | -9.77% | -11.69% | -4.35% | 22.76% | 6.23% | 4.71% |
| Effective Tax Rate | - | - | - | 18.09% | - | - |
| Advertising Expenses | - | - | - | - | 1.16 | 2.06 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.